Get the Stockscreener App
4.04
1.25%
0.05
Pre-market:
4.02
-0.02
-0.50%
X 4 Pharmaceuticals Inc stock is traded at $4.04, with a volume of 648.08K.
It is up +1.25% in the last 24 hours and up +18.13% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.99
Open:
$3.99
24h Volume:
648.08K
Relative Volume:
0.17
Market Cap:
$90.70M
Revenue:
$32.77M
Net Income/Loss:
$-101.98M
P/E Ratio:
-0.4204
EPS:
-9.6101
Net Cash Flow:
$-112.43M
1W Performance:
+6.32%
1M Performance:
+18.13%
6M Performance:
-6.26%
1Y Performance:
-73.08%
1-Day Range:
$3.91
$4.11
1-Week Range:
$3.66
$4.11
52-Week Range:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.04 | 316.07M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
How to build a dashboard for X4 Pharmaceuticals Inc. stock2025 AllTime Highs & Low Drawdown Investment Strategies - newser.com
Top chart patterns to watch in X4 Pharmaceuticals Inc.July 2025 Market Mood & Reliable Entry Point Alerts - newser.com
Using economic indicators to assess X4 Pharmaceuticals Inc. potentialTrade Volume Report & Safe Entry Zone Identification - newser.com
Why X4 Pharmaceuticals Inc. stock could benefit from AI revolutionWeekly Market Summary & Reliable Intraday Trade Alerts - newser.com
Is X4 Pharmaceuticals Inc. (48Q0) stock a fit for income portfoliosDollar Strength & Free Reliable Trade Execution Plans - newser.com
What moving averages say about X4 Pharmaceuticals Inc.Earnings Growth Summary & Weekly Chart Analysis and Guides - newser.com
Will X4 Pharmaceuticals Inc. stock benefit from commodity pricesDay Trade & Capital Efficiency Focused Strategies - newser.com
Will X4 Pharmaceuticals Inc. stock recover after recent dropPrice Action & Advanced Swing Trade Entry Plans - newser.com
What recovery options are there for X4 Pharmaceuticals Inc.Quarterly Earnings Summary & Community Supported Trade Ideas - newser.com
Will X4 Pharmaceuticals Inc. stock benefit from AI adoptionMarket Performance Summary & AI Forecasted Entry and Exit Points - newser.com
Combining machine learning predictions for X4 Pharmaceuticals Inc.July 2025 Trends & Precise Trade Entry Recommendations - newser.com
Can volume confirm reversal in X4 Pharmaceuticals Inc.Trade Signal Summary & AI Forecasted Entry/Exit Points - newser.com
How dovish Fed policy supports X4 Pharmaceuticals Inc. (48Q0) stockPortfolio Profit Report & Technical Entry and Exit Alerts - newser.com
X4 Pharmaceuticals Inc 48Q0 Stock Analysis and ForecastTechnical Breakout Signals & Double Digit Wealth Tips - earlytimes.in
Published on: 2025-10-28 05:23:25 - newser.com
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million - The Manila Times
X4 Pharmaceuticals Completes $155.3 Million Public Offering of Common Stock - Quiver Quantitative
X4 Pharma (NASDAQ: XFOR) closes $155.3M offering; underwriters' option fully exercised - Stock Titan
Craig Adam R buys x4 pharmaceuticals shares for $249,997 - Investing.com India
Why X4 Pharmaceuticals Inc. stock appeals to dividend seekers2025 Technical Overview & Consistent Profit Alerts - fcp.pa.gov.br
Why X4 Pharmaceuticals Inc. stock is a value investor pickJuly 2025 Gainers & Long Hold Capital Preservation Plans - Fundação Cultural do Pará
X4 Pharmaceuticals announces $145.6 million public offering of common stock - Investing.com
What candlestick patterns are forming on X4 Pharmaceuticals Inc.Earnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
X4 Pharmaceuticals Bolsters Financial Stability Amid Strategic Development - StocksToTrade
X4 Pharmaceuticals Eyes Future Growth with $135 Million Offering - StocksToTrade
X4 Pharmaceuticals’ Public Offering Spurs Market Interest - timothysykes.com
X4 Pharmaceuticals (NASDAQ:XFOR) Upgraded at Zacks Research - Defense World
X4 Pharmaceuticals announces pricing of $135 million underwritten public offering at $2.90 per share - MarketScreener
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering - MarketScreener
X4 Pharmaceuticals (NASDAQ: XFOR) prices $135M offering to fund Phase 3 mavorixafor - Stock Titan
X4 Pharmaceuticals announces proposed underwritten public offering - MarketScreener
X4 Pharmaceuticals (NASDAQ: XFOR) commences equity offering; 30-day 15% option - Stock Titan
X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Does X4 Pharmaceuticals Inc. (48Q0) stock trade below intrinsic value2025 Price Momentum & Weekly High Return Stock Forecasts - newser.com
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
| Baldry Mark | Chief Commercial Officer |
Nov 15 '24 |
Buy |
0.34 |
13,404 |
4,598 |
129,173 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):